Characteristics of NF-pNETs <2 cm Included in the Growth Analysis (115 Tumors From 99 Patients
| . | No. (%) (n = 115) . |
|---|---|
| Location, n (%) | |
| Head | 40 (35) |
| Body-tail | 75 (65) |
| Baseline size mm, mean (±SD) | 10 (±4) |
| Newly diagnosed tumor, n (%) | |
| Yes (negative scans before detection) | 62 (54) |
| No (first scan positive) | 53 (46) |
| FUP in y, median (IQR) | |
| Of the tumor in the analysis | 3 (2–6) |
| After the first scan, including FUP after analysis of size | 5 (3–8) |
| Number of size measurements, median (IQR) | 4 (3–6) |
| 2 measurements, n (%) | 20 (17) |
| 3–5 measurements, n (%) | 62 (54) |
| ≥6 measurements, n (%) | 33 (38) |
| Surgery of the tumor, n (%) | 16 (14) |
| Size largest tumor at pathology in mm, median (IQR) | 17 (14–27) |
| WHO 1/WHO 2/WHO 3, n | 12/4/0 |
| LN metastases, no/yes/NA, n | 2/4/10 |
| Use of SSAs during analysis, n (%) | 18 (16) |
| Age in y (mean ± SD) | |
| First measurement | 43 ± 16 |
| Last measurement | 47 ± 15 |
| Biochemical gastrinoma present, n (%) | 16 (14) |
| . | No. (%) (n = 115) . |
|---|---|
| Location, n (%) | |
| Head | 40 (35) |
| Body-tail | 75 (65) |
| Baseline size mm, mean (±SD) | 10 (±4) |
| Newly diagnosed tumor, n (%) | |
| Yes (negative scans before detection) | 62 (54) |
| No (first scan positive) | 53 (46) |
| FUP in y, median (IQR) | |
| Of the tumor in the analysis | 3 (2–6) |
| After the first scan, including FUP after analysis of size | 5 (3–8) |
| Number of size measurements, median (IQR) | 4 (3–6) |
| 2 measurements, n (%) | 20 (17) |
| 3–5 measurements, n (%) | 62 (54) |
| ≥6 measurements, n (%) | 33 (38) |
| Surgery of the tumor, n (%) | 16 (14) |
| Size largest tumor at pathology in mm, median (IQR) | 17 (14–27) |
| WHO 1/WHO 2/WHO 3, n | 12/4/0 |
| LN metastases, no/yes/NA, n | 2/4/10 |
| Use of SSAs during analysis, n (%) | 18 (16) |
| Age in y (mean ± SD) | |
| First measurement | 43 ± 16 |
| Last measurement | 47 ± 15 |
| Biochemical gastrinoma present, n (%) | 16 (14) |
Abbreviations: FUP, follow-up; LN, lymph node; NA, not available; WHO, World Health Organization.
Characteristics of NF-pNETs <2 cm Included in the Growth Analysis (115 Tumors From 99 Patients
| . | No. (%) (n = 115) . |
|---|---|
| Location, n (%) | |
| Head | 40 (35) |
| Body-tail | 75 (65) |
| Baseline size mm, mean (±SD) | 10 (±4) |
| Newly diagnosed tumor, n (%) | |
| Yes (negative scans before detection) | 62 (54) |
| No (first scan positive) | 53 (46) |
| FUP in y, median (IQR) | |
| Of the tumor in the analysis | 3 (2–6) |
| After the first scan, including FUP after analysis of size | 5 (3–8) |
| Number of size measurements, median (IQR) | 4 (3–6) |
| 2 measurements, n (%) | 20 (17) |
| 3–5 measurements, n (%) | 62 (54) |
| ≥6 measurements, n (%) | 33 (38) |
| Surgery of the tumor, n (%) | 16 (14) |
| Size largest tumor at pathology in mm, median (IQR) | 17 (14–27) |
| WHO 1/WHO 2/WHO 3, n | 12/4/0 |
| LN metastases, no/yes/NA, n | 2/4/10 |
| Use of SSAs during analysis, n (%) | 18 (16) |
| Age in y (mean ± SD) | |
| First measurement | 43 ± 16 |
| Last measurement | 47 ± 15 |
| Biochemical gastrinoma present, n (%) | 16 (14) |
| . | No. (%) (n = 115) . |
|---|---|
| Location, n (%) | |
| Head | 40 (35) |
| Body-tail | 75 (65) |
| Baseline size mm, mean (±SD) | 10 (±4) |
| Newly diagnosed tumor, n (%) | |
| Yes (negative scans before detection) | 62 (54) |
| No (first scan positive) | 53 (46) |
| FUP in y, median (IQR) | |
| Of the tumor in the analysis | 3 (2–6) |
| After the first scan, including FUP after analysis of size | 5 (3–8) |
| Number of size measurements, median (IQR) | 4 (3–6) |
| 2 measurements, n (%) | 20 (17) |
| 3–5 measurements, n (%) | 62 (54) |
| ≥6 measurements, n (%) | 33 (38) |
| Surgery of the tumor, n (%) | 16 (14) |
| Size largest tumor at pathology in mm, median (IQR) | 17 (14–27) |
| WHO 1/WHO 2/WHO 3, n | 12/4/0 |
| LN metastases, no/yes/NA, n | 2/4/10 |
| Use of SSAs during analysis, n (%) | 18 (16) |
| Age in y (mean ± SD) | |
| First measurement | 43 ± 16 |
| Last measurement | 47 ± 15 |
| Biochemical gastrinoma present, n (%) | 16 (14) |
Abbreviations: FUP, follow-up; LN, lymph node; NA, not available; WHO, World Health Organization.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
